Publication:
Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification

dc.contributor.authorSunisa Chirakulen_US
dc.contributor.authorNawarat Somprasongen_US
dc.contributor.authorMichael H. Norrisen_US
dc.contributor.authorVanaporn Wuthiekanunen_US
dc.contributor.authorNarisara Chantratitaen_US
dc.contributor.authorApichai Tuanyoken_US
dc.contributor.authorHerbert P. Schweizeren_US
dc.contributor.otherUniversity of Floridaen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2020-01-27T09:51:17Z
dc.date.available2020-01-27T09:51:17Z
dc.date.issued2019-05-01en_US
dc.description.abstract© 2019 Elsevier Ltd Ceftazidime (CAZ) is the antibiotic of choice for the treatment of Burkholderia pseudomallei infection (melioidosis). The chromosomally-encoded PenA β-lactamase possesses weak cephalosporinase activity. The wild-type penA gene confers clinically significant CAZ resistance only when overexpressed due to a promoter mutation, transcriptional antitermination or by gene duplication and amplification (GDA). Here we characterise a reversible 33-kb GDA event involving wild-type penA in a CAZ-resistant B. pseudomallei clinical isolate from Thailand. We show that duplication arises from exchanges between short (<10 bp) chromosomal sequences, which in this example consist of 4-bp repeats flanked by 3-bp inverted repeats. GDA involving β-lactamases may be a common CAZ resistance mechanism in B. pseudomallei.en_US
dc.identifier.citationInternational Journal of Antimicrobial Agents. Vol.53, No.5 (2019), 582-588en_US
dc.identifier.doi10.1016/j.ijantimicag.2019.01.003en_US
dc.identifier.issn18727913en_US
dc.identifier.issn09248579en_US
dc.identifier.other2-s2.0-85061932818en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/51672
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061932818&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleBurkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplificationen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061932818&origin=inwarden_US

Files

Collections